In This Section

Home / Blurb / Discussion List

FDA Approves Cabozantinib for Previously Treated HCC

Jan 15, 2019, 13:07 PM
On January 14, Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Read the full Exelixis, Inc. press release here.

Posted 1/15/2019

Leave a comment